Elexacaftor/Tezacaftor/Ivacaftor use in Pediatric Cystic Fibrosis Patients with Advanced Liver Disease

This publication has 19 references indexed in Scilit:

• Toward a Broader Understanding of Cystic Fibrosis Epidemiology and Its Impact on Clinical Manifestations
  Clinics in Chest Medicine, 2022
• Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment
  European Journal of Drug Metabolism and Pharmacokinetics, 2022
• Current state of CFTR modulators for treatment of Cystic Fibrosis
  Current Opinion in Pharmacology, 2022
• Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor
  Journal of Cystic Fibrosis, 2022
• A case of self-limited drug induced liver injury under treatment with elexacaftor/tezacaftor/ivacaftor: When it is worth taking the risk
  Journal of Cystic Fibrosis, 2021
• Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis
  Journal of Cystic Fibrosis, 2021
• Hepatic Manifestations of Cystic Fibrosis
  Clinics in Liver Disease, 2019
• Ursodeoxycholic acid for cystic fibrosis-related liver disease
  2014
• Cirrhosis and other liver disease in cystic fibrosis
  Journal of Cystic Fibrosis, 2013
• Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction
  European Journal of Clinical Pharmacology, 2008